Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a

Repeat Procedure Compared to TAXUS(R) at Two Years

WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent meta-analysis of Abbott's SPIRIT II and SPIRIT III randomized clinical trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary Stent System continues to deliver clinically significant benefits for patients compared to the TAXUS(R) paclitaxel-eluting coronary stent system out to two years. In this meta-analysis, which included patients from the United States, Europe and Asia-Pacific, XIENCE V demonstrated clinical superiority to TAXUS in the endpoints of target vessel failure (TVF) and major adverse cardiac events (MACE) at two years. XIENCE V also demonstrated significantly lower clinical events rates than TAXUS in the key efficacy (target lesion revascularization) and safety (cardiac death or heart attack) components of MACE at two years. The results are being presented by Gregg W. Stone, M.D., principal investigator of the SPIRIT III trial, during the Cardiovascular Research Foundation's 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

"The pooled results from the SPIRIT II and SPIRIT III trials demonstrate that XIENCE V is safer and provides greater efficacy than TAXUS at two years," said Dr. Stone, professor of medicine at Columbia University Medical Center and chairman, Cardiovascular Research Foundation, New York. "In the meta-analysis at two years, XIENCE V compared to TAXUS demonstrated statistically significant reductions in the combined measure of all-cause death or heart attack, as well as further reducing the need for repeat cardiac procedures -- reinforcing that XIENCE V is a true second-generation stent, which results in improved patient outcomes."

The meta-analysis of 1,302 patients from the SPIRIT I
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...wswire/ -- MedNet Solutions, a global life science...nical study management systems, today announced th...inical technology solution, has been certified by ... (CDISC) as complying with the Operational Data Mo...s MedNet,s commitment to streamlining the entire c...
(Date:12/1/2009)...Dec. 1 The educational r..... Improving Life," created by Lilly USA (NYSE: ...th.com/value_of_medicine.jsp . The booklet support...tter" and encourages an open dialogue with patient...utical industry practices. ,, "Today, Lilly an...
(Date:12/1/2009)...wswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex...censed to Chrono Nutraceuticals LLC exclusive righ... release dietary supplements using SCOLR,s proprie...n, SCOLR granted Chrono rights to manufacture and ...a nonexclusive basis. Chrono paid SCOLR $25,000 u...
Breaking Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 2Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 3Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 4SCOLR Pharma, Inc. Licenses Dietary Supplements 2SCOLR Pharma, Inc. Licenses Dietary Supplements 3Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31 2009 14556 1Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31 2009 14556 2Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31 2009 14556 3Infant sucking habits may affect how baby talks 10453 1Infant sucking habits may affect how baby talks 10453 2NHP Announces Third Quarter Earnings Release Date and Webcast Conference Call 59874 1NHP Announces Third Quarter Earnings Release Date and Webcast Conference Call 59874 2
...25 Data from a 52-week phase 3,study (LEADTM 3) o...-daily,human GLP-1 analog, were published online t...ide, when taken alone, produces statistically,sign...control in patients,with early type 2 diabetes, as...i-diabetic drug. Moreover, the treatment with lira...
.... 25 Snack-sized quantities of,walnuts slow cance...lot,study published in the current issue of the pe...cher W. Elaine Hardman, Ph.D., of Marshall,s Joan ...esigned to determine whether mice,that got part of...t cancer,growth than a group eating a diet more ty...
Other Medicine Technology:Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 2Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 3Eating Walnuts Slows Cancer Growth, Laboratory Study Finds 2
(Date:12/1/2009)..., , FORT LAUDERDALE, Fla., Dec. 1 /PRNews... of patient enrollment in the randomized clinical ...g Stent (Combo Stent). ,, A prospective, random... E valuation of an ablu M inal sirolimus coat ... patients at up to 20 sites in Asia, Australia, Eu...
(Date:12/1/2009)... (December 1, 2009) The ADEAGies Foundation will ...hievement Award at the Gies Awards celebration to ...n conjunction with the 2010 ADEA Annual Session & ... Innovation, and Achievement recognize contributio...tion initiatives. For a complete listing of Gies A...
(Date:12/1/2009)... Uninsured patients in California are unable to su...dical care at hospitals despite recent state legis...ording to a new study. , Posing as low-income un...ates from less than one-third of the hospitals the... much higher than those allowed under California l...
(Date:12/1/2009)...ethod improves diagnosis of benign versus cancerou...Dec. 1 (HealthDay News) -- When used with ultrasou...us and benign breast lesions, which reduces unnece...About 80 percent of breast lesions that are biopsi...n Cancer Society. , "There,s a lot of room to i...
(Date:12/1/2009)... Lumension announces gener... Security Suite to deliver end-to-end endpoint man...ent and single management console architecture. ,...cember 1, 2009 -- Lumension, a global leader in en... new Lumension® Endpoint Management and Secur...
Breaking Medicine News(10 mins):Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:The Forsyth Institute receives the William J. Gies Award for outstanding achievement 2Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:Ultrasound With Elastography May Cut Down on Biopsies 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6
...percent of the Market by 2013, According to a New ...., May 13 Decision Resources, one of the world,s ...armaceutical and healthcare issues, finds that the...will be fueled by an increased uptake of antimetab...
... JEFFERSONS RESTAURANT VIP PREMIERE GALA, What...nday, May 18, 2009, Where: 1033 Jefferson Stre...on Street is known for its legendary live concerts...tic location. In keeping with its pioneering legac...
...iver disease and characterized by excessive collag...evious work, p90RSK is observed significantly up-r...e I levels in rat liver fibrosis. But detail mecha...y addresses this question. The research team led ...
... B (NPR-B) gene was expressed in gastric smooth mu...on was increased in diabetic rats. These results s... signal is up-regulated and it may contribute to d...ed complication of long-standing diabetes. Symptom...
...CE) study estimates prevalence of 3 to 8 million w...NGTON, May 13 Three to eight million women in the.... This newly released prevalence number, presente... has IC and what it is results from an expansive a...
...oudly announce positive results for the CriticalPo...and Products 2nd annual national survey. , , ENGL...he positive customer satisfaction results for the ...harmacy Purchasing and Products in its 2nd annual...
Other Medicine News:Health News:India's Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013 2Health News:Belmont University Graduate Launches Healthy Soul Food Restaurant on Nashville's Historic Jefferson Street 2Health News:NPs-NPR-B/pGC-cGMP signal pathway is involved in diabetic gastroparesis 2Health News:Prevalence of Interstitial Cystitis in U.S. Much Larger Than Previously Believed 2Health News:CriticalPoint(TM) Training Rated 'Excellent' in Customer Satisfaction 2Health News:CriticalPoint(TM) Training Rated 'Excellent' in Customer Satisfaction 3
Acri.Sil-oI 1000
Ispan SF6 Intraocular Gases
Silikon 1000 Silicone Oil
Foreign body spud
Medicine Products: